Probiotic‐Inspired Nanomedicine Restores Intestinal Homeostasis in Colitis by Regulating Redox Balance, Immune Responses, and the Gut Microbiome

Xu, Jiaqi; Xu, Junchao; Shi, Tongfei; Zhang, Yinlong; Chen, Fangman; Yang, Chao; Guo, Xueyuan; Shao, Dan; Leong, Kam W.; Nie, Guangjun

doi:10.1002/adma.202207890

Cited by 54 publications

(45 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, SEM@EcN effectively increased proportion of short‐chain fatty acid–producing bacterium strains, and reduced the proportion of pathogenic bacterium strains to effectively enhance the prevention and management of IBD. [ 110 ]…”

Section: Biomedical Applications Of Hybrid Bacteria Systemsmentioning

confidence: 99%

“…Moreover, SEM@EcN effectively increased proportion of short-chain fatty acid-producing bacterium strains, and reduced the proportion of pathogenic bacterium strains to effectively enhance the prevention and management of IBD. [110] One of the most important factors limiting clinical treatment efficacy of oral delivery of probiotics is the survival and colonization of probiotics. Hybrid bacteria systems harness surface decoration technology and nanotechnology to not only endow probiotics with high viability and bioavailability, but also additional exogenous functions.…”

Section: Other Diseasesmentioning

confidence: 99%

See 1 more Smart Citation

Hybrid Bacteria System with Nanomaterials for Tumor Therapy

Zhang

Zhao

2023

Advanced NanoBiomed Research

View full text Add to dashboard Cite

Malignant tumors are still considered as one of leading causes of human motility worldwide due to the complexity and heterogenicity of tumor microenvironment (TME). [1] Current therapeutic efficacy of tumor treatments mainly including surgery, chemotherapy, and radiotherapy are not optimistic, which usually have severe side effects, limited tumor permeation, poor prognosis, and high recurrence and metastasis rates. [2] Although emerging tumor immunotherapy has been regarded as the milestone in tumor therapy, some challenges also hinder its clinical therapeutic efficacy. For example, the immune checkpoint blockade therapy with programmed cell death 1-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4, as a revolutionary emerging immunotherapy, is faced with limited immune responses in most patients owing to immunotherapy resistance. [3] Well-known chimeric antigen receipt T (CAR-T) cell therapy is regarded as a breakthrough technology in the clinical therapy of tumors. Most CAR-T therapies have achieved encouraging efficacy in hematological diseases, but the further application in solid tumors requires to be improved. [4] Therefore, with the improved understanding of tumor therapy, some newly emerging therapeutic approaches have been proposed.Bacteria as a natural prokaryotic cell, with inherent tumor targeting and autonomy-driven properties in cancer therapy, are undergoing a rapid development (Figure 1). As early as the 19th century, Coley first leveraged Streptococcus pyogenes as bacterial agents to alleviate sarcoma. [5] Ever since this discovery, researchers have increasing attentions in utilizing microorganisms to fight against tumors such as Clostridium, Listeria, Escherichia. [6] Among them, the emergence of bacillus Calmette-Guérin (BCG), composed of live Mycobacterium tuberculosis, are applied in the clinical therapy of bladder cancer. [7] However, the first generation of bacterial therapy based on natural, live, or inactivated bacteria mainly depends on the inherent antitumor properties including tumor-targeting and immunogenicity of bacteria, accompanying with the septic shock and infectious risk. [8] With the in-depth understanding of biological technologies, the second generation of bacterial therapy based on engineered bacteria utilizes the recombinant DNA technology to achieve the spatiotemporally precise manipulation of the bacterial behavior and function. [9] Compared with the first generation, genetically engineered bacteria such as attenuated Salmonella (VNP20009) have attenuated systemic toxicity by selectively knocking out of some genes of virulence factors. [10] Moreover, utilizing genetic engineering technology, bacteria are programmatically induced to synthesize anticancer agents and certain tumor-targeting molecules in situ under the endogenous and exogenous stimuli, which significantly improved therapeutic efficacy of tumors. In conclusion, the superiorities of using natural or engineered bacteria to treating tumors are owing to the following aspects. First, some

show abstract

Section: Biomedical Applications Of Hybrid Bacteria Systemsmentioning

confidence: 99%

Section: Other Diseasesmentioning

confidence: 99%

Hybrid Bacteria System with Nanomaterials for Tumor Therapy

Zhang

Zhao

2023

Advanced NanoBiomed Research

View full text Add to dashboard Cite

show abstract

“…In the 3% DSS-induced colitis mouse model described above, orally administered Dir-labeled probiotic-derived OMVs could effectively accumulate in colonic mucosa, 18 h after administration in DSS-inflamed colitis mice (Figure 2a,b). 37 On the contrary, this OMVs were not observed in the colon tissue of normal mice. Given the promising outcomes of nanoprobiotics described above, we then assessed the therapeutic efficacy against colitis.…”

mentioning

confidence: 91%

Nanoprobiotics for Remolding the Pro-inflammatory Microenvironment and Microbiome in the Treatment of Colitis

Li,

Sun,

Liu

et al. 2023

Nano Lett.

View full text Add to dashboard Cite

Despite the great progress of current bacterially based biotherapeutics, their unsatisfying efficacy and underlying safety problems have limited their clinical application. Herein, inspired by probiotic Escherichia coli strain Nissle 1917, probioticderived outer membrane vesicles (OMVs) are found to serve as an effective therapeutic platform for the treatment of inflammatory bowel disease (IBD). To further enhance the therapeutic effect, the probiotic-derived OMV-encapsulating manganese dioxide nanozymes are constructed, named nanoprobiotics, which can adhere to inflamed colonic epithelium and eliminate intestinal excess reactive oxygen species in the murine IBD model. Moreover, combined with the anti-inflammatory medicine metformin, nanoprobiotics could further remold the pro-inflammatory microenvironment, improve the overall richness and diversity of the gut microbiota, and exhibit better therapeutic efficacy than commercial IBD chemotherapeutics. Importantly, insignificant overt systemic toxicity in this treatment was observed. By integrating cytokine storm calm with biotherapy, we develop a safe and effective bionanoplatform for the effective treatment of inflammation-mediated intestinal diseases.

show abstract

“…[9,10] With a deeper understanding on the pathogenesis of IBD, nanosized formulations which can integrate both therapeutic and diagnostic capabilities have attracted tremendous attention in IBD treatment. [11][12][13] Currently, nanomedicines constructed for IBD management can be made from lipids, liposomes, polymers, peptides, inorganic nanozymes, and extracellular vesicles, showing a broad range of sizes from a few to 1000 nanometers. Compared with conventional free drugs including anti-inflammatory molecules, immunosuppressants, and chemotherapeutic drugs or free imaging agents, these advanced nanotherapeutics encapsulated drugs or imaging agents exhibit prolonged plasma circulation time, optimized biodistribution profile, as well as improved bioavailability and enhanced therapeutic outcomes.…”

Section: Introductionmentioning

confidence: 99%

Advanced Nanomedicine: Redefining Therapeutic Paradigms for Inflammatory Bowel Disease

Zhang

Wang

Sun

et al. 2023

Adv Healthcare Materials

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD), a chronic and recurrent gastrointestinal inflammatory disorder with a variety of painful clinical manifestations and an increased risk of cancerization or death, has become an emerging challenge to global healthcare due to its rapidly increasing incidence. At present, there is no efficient cure against IBD because of the elusive etiology and pathogenesis of IBD. Therefore, the development of alternative therapeutic strategies with positive clinical efficacy and reduced side effects is urgently needed. In recent years, the great prosperity of nanomedicine promoted by a variety of advanced nanomaterials is redefining more attractive and promising therapeutic strategies for IBD owing to their advantages in the physiological stability, bioavailability, and targeting of inflammatory sites. In this review, firstly the basic characteristics of healthy and inflammatory intestinal microenvironments are presented. Then, different administration routes and targeting strategies of nanotherapeutics for IBD treatment are reviewed. Subsequently, a specific focus is placed on the introduction of nanotherapeutic treatments based on different IBD pathogenesis. Finally, some future challenges and perspectives of the currently developed nanomedicines for IBD treatment are provided. It is believed that the above topics will attract researchers from various fields including medicine, biological sciences, materials, chemistry and pharmaceutics.

show abstract

Probiotic‐Inspired Nanomedicine Restores Intestinal Homeostasis in Colitis by Regulating Redox Balance, Immune Responses, and the Gut Microbiome

Cited by 54 publications

References 73 publications

Hybrid Bacteria System with Nanomaterials for Tumor Therapy

Hybrid Bacteria System with Nanomaterials for Tumor Therapy

Nanoprobiotics for Remolding the Pro-inflammatory Microenvironment and Microbiome in the Treatment of Colitis

Advanced Nanomedicine: Redefining Therapeutic Paradigms for Inflammatory Bowel Disease

Contact Info

Product

Resources

About